Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for TNGX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 -38.87M
March 31, 2026 -44.36M
December 31, 2025 -29.72M
September 30, 2025 -30.95M
June 30, 2025 -36.52M
March 31, 2025 -41.70M
December 31, 2024 -36.65M
September 30, 2024 -33.39M
June 30, 2024 -23.61M
March 31, 2024 -37.86M
December 31, 2023 -27.47M
September 30, 2023 -31.14M
Date Value
June 30, 2023 -24.47M
March 31, 2023 -34.91M
December 31, 2022 -28.27M
September 30, 2022 -19.61M
June 30, 2022 -31.54M
March 31, 2022 -29.66M
December 31, 2021 -16.90M
September 30, 2021 -21.49M
June 30, 2021 -7.518M
March 31, 2021 -13.61M
December 31, 2020 -18.06M
September 30, 2020 88.14M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Revolution Medicines, Inc. -387.32M
Erasca, Inc. -27.27M
NovelStem International Corp. -0.0336M
Brainstorm Cell Therapeutics, Inc. -0.895M
Summit Therapeutics, Inc. -140.55M